Abstract:Although macrophage activation syndrome (MAS) develops in some patients with chronic granulomatous disease (CGD), all of the reported cases have been associated with pathogenic microbial infections. We report a 2-year-old boy with CGD-associated colitis who suffered from MAS without any clinical signs of a microbial infection. He was treated with 1 course of methylprednisolone pulse therapy and the clinical symptoms improved; however, the colitis was difficult to control even with immunosuppressive drugs, and … Show more
“…In most of the younger CGD patients reported (<4 years), macrophage activation developed at or before the diagnosis of CGD. In the majority of cases, the macrophage activation was associated with severe infectious events and in one child suffering from CGD-associated colitis with no clinical signs of bacterial infections (64,65). Treatment includes a wide range of MAS-directed treatment regimens, including corticosteroids alone or in combination with IVIG or cyclosporine, and generally, contrary to the familial form, MAS in CGD patients showed a good clinical outcome (64,66).…”
Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by defects in the genes encoding any of the NADPH oxidase components responsible for the respiratory burst of phagocytic leukocytes. CGD is a genetically heterogeneous disease with an X-linked recessive (XR-CGD) form caused by mutations in the CYBB gene encoding the gp91(phox) protein, and an autosomal recessive (AR-CGD) form caused by mutations in the CYBA, NCF1, NCF2, or NCF4 genes encoding p22(phox) , p47(phox) , p67(phox) , and p40(phox) , respectively. Patients suffering from this disease are susceptible to severe life-threatening bacterial and fungal infections and excessive inflammation characterized by granuloma formation in any organ, for instance, the gastrointestinal and genitourinary tract. An early diagnosis of and the prompt treatment for these conditions are crucial for an optimal outcome of affected patients. To prevent infections, CGD patients should receive lifelong antibiotics and antifungal prophylaxis. These two measures, as well as newer more effective antimicrobials, have significantly modified the natural history of CGD, resulting in a remarkable change in overall survival, which is now around 90%, reaching well into adulthood. At present, hematopoietic stem cell transplantation (HSCT) is the only definitive treatment that can cure CGD and reverse organ dysfunction. Timing, donor selection, and conditioning regimens remain the key points of this therapy. In recent years, gene therapy (GT) for XR-CGD has been proposed as an alternative to HSCT for CGD patients without a matched donor. After the failure of the first trials performed with retroviral vectors, some groups have proposed the use of regulated SIN-lentiviral vectors targeting gp91(phox) expression in myeloid cells to increase the safety and efficacy of the GT protocols.
“…In most of the younger CGD patients reported (<4 years), macrophage activation developed at or before the diagnosis of CGD. In the majority of cases, the macrophage activation was associated with severe infectious events and in one child suffering from CGD-associated colitis with no clinical signs of bacterial infections (64,65). Treatment includes a wide range of MAS-directed treatment regimens, including corticosteroids alone or in combination with IVIG or cyclosporine, and generally, contrary to the familial form, MAS in CGD patients showed a good clinical outcome (64,66).…”
Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by defects in the genes encoding any of the NADPH oxidase components responsible for the respiratory burst of phagocytic leukocytes. CGD is a genetically heterogeneous disease with an X-linked recessive (XR-CGD) form caused by mutations in the CYBB gene encoding the gp91(phox) protein, and an autosomal recessive (AR-CGD) form caused by mutations in the CYBA, NCF1, NCF2, or NCF4 genes encoding p22(phox) , p47(phox) , p67(phox) , and p40(phox) , respectively. Patients suffering from this disease are susceptible to severe life-threatening bacterial and fungal infections and excessive inflammation characterized by granuloma formation in any organ, for instance, the gastrointestinal and genitourinary tract. An early diagnosis of and the prompt treatment for these conditions are crucial for an optimal outcome of affected patients. To prevent infections, CGD patients should receive lifelong antibiotics and antifungal prophylaxis. These two measures, as well as newer more effective antimicrobials, have significantly modified the natural history of CGD, resulting in a remarkable change in overall survival, which is now around 90%, reaching well into adulthood. At present, hematopoietic stem cell transplantation (HSCT) is the only definitive treatment that can cure CGD and reverse organ dysfunction. Timing, donor selection, and conditioning regimens remain the key points of this therapy. In recent years, gene therapy (GT) for XR-CGD has been proposed as an alternative to HSCT for CGD patients without a matched donor. After the failure of the first trials performed with retroviral vectors, some groups have proposed the use of regulated SIN-lentiviral vectors targeting gp91(phox) expression in myeloid cells to increase the safety and efficacy of the GT protocols.
“…A distinctive component of CGD is its association with inflammatory conditions, often unrelated to infection, including granulomatous inflammation in the gastrointestinal and genitourinary tracts, discoid lupus-like lesions, and macrophage activation syndrome. [2][3][4][5][6] Moreover, NADPH oxidase gene variants are linked to lupus, rheumatoid arthritis, and inflammatory bowel disease. [7][8][9][10] However, insights into the role of NADPH oxidase in regulating inflammatory responses to sterile endogenous ligands are lacking, an important question given the association of NADPH oxidase deficiency with noninfectious inflammatory disorders.…”
“…Organisms implicated include Haemophilus influenzae and Streptococci spp. [7,8]. Another common problem during childhood is osteomyelitis, which often presents in the same manner as septic arthritis, with the inability to weight-bear and a swollen joint.…”
Section: Discussionmentioning
confidence: 97%
“…A variety of other conditions have been described in the literature to be associated with macrophage activation syndrome, including juvenile rheumatoid arthritis, chronic granulomatous colitis [7], Still's disease [13], and SLE [9,10].…”
Section: Discussionmentioning
confidence: 98%
“…Macrophage activation syndrome is a potentially lifethreatening complication of several paediatric rheumatological conditions, most commonly including systemic juvenile idiopathic arthritis (sJIA), but also systemic lupus erythmatosus (SLE) and granulomatous disease [6][7][8][9][10]. The incidence of JIA in the UK is 1/10 000, of which the literature suggest that 10-20% of cases show systemic onset (sJIA), which is recognized to be associated with worse morbidity, functional outcomes and overall prognosis.…”
We present an interesting case of macrophage activation syndrome in a 2-year-old, with no previous rheumatological diagnoses, incorrectly diagnosed with septic arthritis, to highlight the diagnostic difficulties, especially in small hospital units. We aim to present the similarities between the two conditions and to summarize the clinical, radiological and epidemiological features of macrophage activation syndrome, an underdiagnosed condition. A review of the current literature was performed, and a diagnostic algorithm was created. No current set treatment regimen exists, but current recommendations have been included. We have demonstrated the pitfalls in diagnosis and the importance of immediate treatment in optimizing prognosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.